Key Statistics for BTG
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (GBP) (ttm)
|Est. EPS (GBP) (03/2014)
|Est. PEG Ratio
|Market Cap (M GBP)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|Cash Dividend (GBp)
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for BTG
- Net Income (M/GBP)
BTG plc licenses, develops and commercializes pharmaceuticals and has a pipeline of development programs targeting neurological and other disorders, including varicose veins. The Company also has a substantial and growing revenue stream of milestone payments and royalties from out-licensed products.
More Company Profile & Key Executives for BTG
|Louise MakinChief Executive Officer||Rolf SoderstromCFO/Executive Director|
|Andy BurrowsDirector:Investor Relations||Paul MussendenSecretary|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.